News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
BioNTech aims to develop the first mRNA-based malaria vaccine, hoping to reach clinical trials by 2022. Meanwhile, it is also exploring possibilities to set up mRNA manufacturing facilities on the African continent – which could potentially be used for...
AC Immune will acquire Affiris’ portfolio of therapeutics targeting alpha-synuclein (a-syn), which includes a vaccine candidate for the treatment of Parkinson’s disease.
Cytiva and Pall Corporation, both subsidiaries of Danaher Corporation, have announced they are to invest US$1.5bn to expand manufacturing capacity across 13 sites globally
Absci Corp, a Vancouver, Washington headquartered synthetic biology company developing technologies to accelerate drug discovery, has gone public.